Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology

The Biology of LFS and Core Cancers

At a Glance

Li-Fraumeni Syndrome (LFS) is caused by a mutation in the TP53 gene, impairing the body's ability to repair damaged DNA. This significantly increases the risk of developing five core cancers: sarcomas, early-onset breast cancer, brain tumors, adrenocortical carcinoma, and leukemias.

Understanding the biology of Li-Fraumeni Syndrome (LFS) begins with a single gene: TP53. This gene is the blueprint for a protein called p53, which is so vital to health that scientists call it the “guardian of the genome” [1][2].

The Guardian’s Job

In a typical cell, the p53 protein acts like a security guard and repair technician [1]. When a cell’s DNA is damaged by things like sunlight, chemicals, or aging, p53 steps in to:

  • Stop growth: It pauses the cell so it cannot divide and spread the damage [1].
  • Fix the damage: It activates DNA repair systems to mend the blueprint [1].
  • Self-destruct: If the damage is too severe to fix, p53 triggers apoptosis (programmed cell death) so the damaged cell doesn’t become a tumor [1].

Because individuals with LFS have a weakened ability to repair DNA damage, everyday prevention is crucial. This includes practicing rigorous sun protection (like wearing sunscreen and protective clothing) to minimize unnecessary DNA damage to skin cells [3].

The Core Cancers of LFS

While LFS can increase the risk of almost any cancer, five specific “core” types are most common [4][5]:

  1. Sarcomas: These are cancers of the “connective tissues,” such as osteosarcoma (bone cancer) and soft tissue sarcomas (like rhabdomyosarcoma in muscles) [4][6].
  2. Breast Cancer: This is the most common cancer in women with LFS, often occurring at a very early age (before 35) [7][4].
  3. Brain Tumors: A wide variety of brain tumors can occur, including choroid plexus carcinoma, which is a rare tumor that primarily affects young children [8][9].
  4. Adrenocortical Carcinoma (ACC): This is a cancer of the adrenal glands (small glands on top of the kidneys). It is a hallmark of LFS in children [10][11].
  5. Leukemias: These are cancers of the blood-forming tissues and are part of the broader LFS spectrum [4][6].

Differences Between Children and Adults

LFS presents differently depending on age. In childhood, the most frequent diagnoses are adrenocortical carcinomas, brain tumors, and soft tissue sarcomas [10][12]. Parents should be aware that ACC can sometimes cause “virilization”—early signs of puberty like a deep voice, acne, or rapid growth in height [10][11]. Because of this risk, parents should closely track their child’s growth charts and immediately report any sudden growth spurts or early puberty signs to their pediatrician.

In adulthood, the spectrum shifts. Women face a very high risk of early-onset breast cancer, while both men and women continue to be at risk for sarcomas, brain tumors, and other epithelial cancers like lung or colon cancer [7][4].

Classic vs. Attenuated LFS

Not everyone with a TP53 mutation has the same experience:

  • Classic LFS: This follows a strict family history pattern of early-onset cancers [13].
  • Attenuated LFS: Also called Li-Fraumeni-like (LFL) syndrome, this refers to families who have TP53 mutations but may not meet the strict “classic” rules. These individuals might have a later age of cancer onset or a slightly lower lifetime risk [14][15].

Common questions in this guide

What is the role of the TP53 gene in Li-Fraumeni Syndrome?
The TP53 gene produces the p53 protein, often called the guardian of the genome. It helps repair damaged DNA or destroys severely damaged cells before they can become tumors. In LFS, a mutation in this gene weakens the body's ability to stop cancer growth.
What are the core cancers of Li-Fraumeni Syndrome?
The five most common core cancers associated with LFS are sarcomas (bone and soft tissue cancers), early-onset breast cancer, brain tumors, adrenocortical carcinoma (cancer of the adrenal glands), and leukemias.
How do LFS cancer risks differ between children and adults?
In childhood, LFS frequently presents as adrenocortical carcinomas, brain tumors, or soft tissue sarcomas. In adulthood, the spectrum shifts, with women facing a high risk of early-onset breast cancer, while both men and women are at risk for sarcomas and other cancers.
What is the difference between classic and attenuated LFS?
Classic LFS follows a strict family history pattern characterized by very early-onset cancers. Attenuated LFS involves families with TP53 mutations who may experience a later age of cancer onset or a slightly lower lifetime cancer risk than the classic form.
What signs of adrenocortical carcinoma (ACC) should parents look for?
ACC is a cancer of the adrenal glands that can cause 'virilization' in children. This causes early signs of puberty, such as a deepening voice, acne, or rapid growth spurts. Parents should track their child's growth and report any sudden changes to their pediatrician.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific TP53 mutation, do I have 'classic' or 'attenuated' Li-Fraumeni syndrome?
  2. 2.Are there specific types of cancer I should be more concerned about based on my age and gender?
  3. 3.How does a 'gain-of-function' mutation differ from a 'loss-of-function' mutation in terms of my cancer risk?
  4. 4.Should my siblings or parents be tested even if I am the first person in the family to be diagnosed?
  5. 5.What non-genotoxic treatment options are available if a tumor is found, to avoid the risk of radiation-induced cancers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Recent Advances in p53.

    D'Orazi G

    Biomolecules 2021; (11(2)) doi:10.3390/biom11020211.

    PMID: 33546313
  2. 2

    Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy.

    Chauhan S, Jaiswal S, Jakhmola V, et al.

    Cancer letters 2024; (588()):216766 doi:10.1016/j.canlet.2024.216766.

    PMID: 38408603
  3. 3

    [Li-Fraumeni syndrome].

    Keymling M, Schlemmer HP, Kratz C, et al.

    Radiologie (Heidelberg, Germany) 2022; (62(12)):1026-1032 doi:10.1007/s00117-022-01071-x.

    PMID: 36166074
  4. 4

    Li-Fraumeni syndrome presenting as cutaneous melanoma in a child: case report and review of literature.

    Baek YS, Seo JY, Song JY, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(4)):e174-e175 doi:10.1111/jdv.15430.

    PMID: 30653764
  5. 5

    Melanoma and Li-Fraumeni syndrome: family history is not essential for screening recommendation.

    Regan H, Marren P

    Clinical and experimental dermatology 2021; (46(8)):1567-1568 doi:10.1111/ced.14748.

    PMID: 34008262
  6. 6

    Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

    Mai PL, Best AF, Peters JA, et al.

    Cancer 2016; (122(23)):3673-3681 doi:10.1002/cncr.30248.

    PMID: 27496084
  7. 7

    Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study.

    Rippinger N, Fischer C, Sinn HP, et al.

    Cancer medicine 2021; (10(21)):7747-7758 doi:10.1002/cam4.4300.

    PMID: 34569185
  8. 8

    Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience.

    Pondrom M, Bougeard G, Karanian M, et al.

    Pediatric blood & cancer 2020; (67(9)):e28486 doi:10.1002/pbc.28486.

    PMID: 32658383
  9. 9

    [A rhabdomyosarcoma patient from a Li-Fraumeni syndrome family: a case report and literature review].

    Xie Y, Zhao WH, Hua Y, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2017; (19(12)):1263-1266.

    PMID: 29237527
  10. 10

    A rare pediatric case of Li-Fraumeni syndrome presenting with virilization symptoms and dual primary malignancies on magnetic resonance imaging and [18F]-fluorodeoxyglucose positron emission tomography/computed tomography.

    Chen J, Ouyang W

    Pediatric radiology 2025; (55(12)):2671-2675 doi:10.1007/s00247-025-06340-0.

    PMID: 40815376
  11. 11

    Management of orbital rhabdomyosarcoma in a child with Li-Fraumeni syndrome.

    Jivraj I, Somers GR, Belliveau MJ, et al.

    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2019; (23(3)):182-185 doi:10.1016/j.jaapos.2019.01.013.

    PMID: 30974170
  12. 12

    Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.

    de Andrade KC, Khincha PP, Hatton JN, et al.

    The Lancet. Oncology 2021; (22(12)):1787-1798 doi:10.1016/S1470-2045(21)00580-5.

    PMID: 34780712
  13. 13

    Performance of LFSPRO TP53 germline carrier risk predictions compared to standard genetic counseling practice on prospectively collected probands.

    Corredor JL, Dodd-Eaton EB, Woodman-Ross J, et al.

    medRxiv : the preprint server for health sciences 2024; doi:10.1101/2024.07.09.24310095.

    PMID: 39040185
  14. 14

    Attenuated Li-Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report.

    Kasahara Y, Takahashi M, Kawamura Y, et al.

    Familial cancer 2026; (25(1)):18 doi:10.1007/s10689-026-00529-4.

    PMID: 41632335
  15. 15

    Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.

    Rana HQ, Gelman R, LaDuca H, et al.

    Journal of the National Cancer Institute 2018; (110(8)):863-870 doi:10.1093/jnci/djy001.

    PMID: 29529297

This page provides educational information about the biology and core cancers associated with Li-Fraumeni Syndrome. It is not intended to replace personalized medical advice from your genetic counselor or oncologist.

Get notified when new evidence is published on Li-Fraumeni syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.